$70.43
2.07% yesterday
Nasdaq, Sep 20, 10:14 pm CET
ISIN
US2521311074
Symbol
DXCM
Sector

DexCom, Inc. Stock price

$70.43
-2.42 3.32% 1M
-62.10 46.86% 6M
-53.66 43.24% YTD
-22.20 23.97% 1Y
-69.01 49.49% 3Y
+31.83 82.46% 5Y
+60.32 596.46% 10Y
Nasdaq, Closing price Fri, Sep 20 2024
-1.49 2.07%
ISIN
US2521311074
Symbol
DXCM
Sector

Key metrics

Market capitalization $28.22b
Enterprise Value $27.70b
P/E (TTM) P/E ratio 43.40
EV/FCF (TTM) EV/FCF 41.62
EV/Sales (TTM) EV/Sales 7.04
P/S ratio (TTM) P/S ratio 7.17
P/B ratio (TTM) P/B ratio 11.59
Revenue growth (TTM) Revenue growth 23.05%
Revenue (TTM) Revenue $3.93b
EBIT (operating result TTM) EBIT $681.50m
Free Cash Flow (TTM) Free Cash Flow $665.50m
Cash position $3.12b
EPS (TTM) EPS $1.62
P/E forward 43.10
P/S forward 7.03
EV/Sales forward 6.90
Short interest 2.07%
Show more

Create a Free Account to create an DexCom, Inc. alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

DexCom, Inc. Stock Analysis

Analyst Opinions

27 Analysts have issued a DexCom, Inc. forecast:

20x Buy
74%
7x Hold
26%

Analyst Opinions

27 Analysts have issued a DexCom, Inc. forecast:

Buy
74%
Hold
26%

Financial data from DexCom, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
3,935 3,935
23% 23%
100%
- Direct Costs 1,466 1,466
22% 22%
37%
2,469 2,469
23% 23%
63%
- Selling and Administrative Expenses 1,040 1,040
12% 12%
26%
- Research and Development Expense 542 542
17% 17%
14%
887 887
46% 46%
23%
- Depreciation and Amortization 205 205
28% 28%
5%
EBIT (Operating Income) EBIT 682 682
52% 52%
17%
Net Profit 667 667
87% 87%
17%

In millions USD.

Don't miss a Thing! We will send you all news about DexCom, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

DexCom, Inc. Stock News

Neutral
PRNewsWire
about 6 hours ago
NEW YORK , Sept. 20, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between January 8, 2024 and July 25, 2024, both dates inclusive (the "Class Period"), of the important October 21, 2024 lead plaintiff deadline.
Neutral
PRNewsWire
about 7 hours ago
LOS ANGELES , Sept. 20, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM).
Neutral
GlobeNewsWire
one day ago
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In DexCom To Contact Him Directly To Discuss Their Options
More DexCom, Inc. News

Company Profile

DexCom, Inc. is a medical device manufacturing company. The firm engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G4 PLATINUM System, DexCom G5 Mobil, DexCom Share and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.

Head office United States
CEO Kevin Sayer
Employees 9,600
Founded 1999
Website www.dexcom.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today